SITUATION 01
We are evaluating a new market
A promising market is not the same as a validated market.
A country can look attractive because of size, growth, competitor activity, distributor interest or internal ambition.
But none of those signals alone answer the question leadership actually has to decide:
Should we commit more time, money and structure here?
WHY THIS MATTERS
The cost of entering too early is not only financial.
A premature move can create:
- a local hire before the market is understood
- a distributor commitment before demand is tested
- investment in stock, travel or support before account potential is clear
- internal distraction around a market that does not deserve priority
- false confidence created by surface-level interest
The real risk is not simply choosing the wrong market.
It is committing before the company knows enough.
WHAT IS USUALLY MISSING
Companies in this situation often already have some information.
They may have:
- desk research
- market-size estimates
- competitor observations
- distributor conversations
- inbound interest
- internal strategic rationale
What is usually missing is live commercial evidence.
That means:
- which accounts actually matter
- who the relevant decision-makers are
- whether credible access is possible
- what the market says when the offer is presented
- what objections repeat
- what constraints appear
- whether opportunities progress beyond initial interest
HOW VIAPORA TREATS THE DOSSIER
VIAPORA does not start by assuming the market is right.
We start by making the hypothesis explicit.
The dossier is structured around:
- the target market or corridor
- the offer context
- the primary ICP
- account criteria
- decision assumptions
- evidence required to support or challenge the case
From there, VIAPORA builds a priority account universe, identifies relevant decision-makers and defines credible access routes.
The hypothesis is then tested through real commercial execution.
Outreach, conversations, qualification, follow-up and opportunity movement create the evidence needed to compare the original thesis with the market response.
The purpose is not to prove the initial idea correct.
The purpose is to make the next decision stronger.
GO / ADJUST / STOP
ME90 moves the company from market hypothesis to market evidence to commercial decision. The likely end-state is not automatically “enter the market.”
GO
Continue.
ADJUST
Revise the market, ICP, offer or access route.
STOP
Do not commit further under the tested conditions.
WHAT EVIDENCE SHOULD EMERGE
A well-treated dossier should progressively make visible:
- which assumptions still hold
- which account types respond most credibly
- which decision-makers matter
- where access is easier or harder than expected
- which objections repeat
- what the market does not understand
- what pricing, delivery or product questions appear
- which conversations progress
- which signals are only interest
- whether continued investment is justified
The evidence should reduce ambiguity.
It should not create artificial certainty.
WHAT THE CLIENT STILL OWNS
VIAPORA can test the market-facing commercial hypothesis.
The client remains the authority on:
- product truth
- technical claims
- delivery feasibility
- pricing approvals
- contractual commitments
- final delivery obligations
The client must also be able to respond when market evidence exposes a technical, pricing, legal or operational question.
A market cannot be validated responsibly if the company cannot answer the market back.
LIKELY MANDATE PATH
ME90 is the primary mandate for this situation.
Its purpose is to move the company from market hypothesis, to market evidence, to commercial decision.
WHEN VIAPORA MAY NOT BE THE RIGHT FIT
VIAPORA may not be the right fit when:
- leadership is only looking for a list of contacts
- the company expects guaranteed contracts or revenue
- no one internally can provide product, pricing or delivery truth
- the company is not prepared to act on qualified market evidence
- the decision to enter has already been made regardless of what the market says
Market entry should start with a decision question
The most useful first question is not: “How quickly can we enter?”
It is: “What would we need to know before this market deserves a larger commitment?”
That is where VIAPORA starts.
If your company is considering a new market and wants evidence before committing fixed structure, discuss the dossier with VIAPORA.